The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network

Trends in Biochemical Sciences

Volumn 27, Issue 9, 2002, Pages 462-467

  Mayo, Lindsey D ^a   Donner, David B ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL DAMAGE; CELL FUNCTION; CELL GROWTH; CELL VIABILITY; CYTOPLASM; DOWN REGULATION; GENE MUTATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; NUCLEAR PROTEINS; PHOSPHORIC MONOESTER HYDROLASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MDM2; PTEN PHOSPHOHYDROLASE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0036710512     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0004(02)02166-7     Document Type: Review

References (63)

1. Jacobson M.D., et al. Programmed cell death in animal development. Cell. 88:1997;347-354.
2. Toker A., Cantley L.C. Signaling through the lipid products of phosphoinositide-3-OH kinase. Nature. 387:1997;673-676.
3. Brazil D.P., Hemmings B.A. Ten years of protein kinase B signaling: a hard Akt to follow. Trends Biochem. Sci. 26:2001;657-664.
4. Dudek H., et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science. 275:1997;661-665.
5. Kulik G., et al. Antiapoptotic signaling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol. Cell. Biol. 17:1997;1595-1606.
6. Sabbatini P., McCormick F. Phosphoinositide 3-OH kinase (PI3K) and PKB/Akt delay the onset of p53-mediated, transcriptionally dependent apoptosis. J. Biol. Chem. 274:1999;24263-24269.
7. Datta S.R., et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 91:1997;231-241.
8. Brunet A., et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 96:1999;857-868.
9. Ozes O.N., et al. NF-κB activation by tumour necrosis factor requires the Akt serine- threonine kinase. Nature. 401:1999;82-85.
10. Sizemore N., et al. Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-κB p65/RelA subunit. Mol. Cell. Biol. 19:1999;4798-4805.
11. Collado M., et al. Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1. J. Biol. Chem. 275:2000;21960-21968.
12. Zhou B.P., et al. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat. Cell Biol. 3:2001;245-252.
13. Cardone M.H., et al. Regulation of cell death protease caspase-9 by phosphorylation. Science. 282:1998;1318-1321.
14. Cho H., et al. Akt1/PKBα is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J. Biol. Chem. 276:2001;38349-38352.
15. Cho H., et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science. 292:2001;1728-1731.
16. Stiles B., et al. Essential role of AKT-1/protein kinase B alpha in PTEN-controlled tumorigenesis. Mol. Cell. Biol. 22:2002;3842-3851.
17. Fujio Y., et al. Activation of Akt2 inhibits anoikis and apoptosis induced by myogenic differentiation. Cell Death Differ. 8:2001;1207-1212.
18. Mayo L.D., Donner D.B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. U. S. A. 98:2001;11598-11603.
19. Zhou B.P., et al. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol. 3:2001;973-982.
20. Ashcroft M., et al. Phosphorylation of HDM2 by Akt. Oncogene. 21:2002;1955-1962.
21. Gottlieb T.M., et al. Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene. 21:2002;1299-1303.
22. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
23. Donehower L.A., et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 356:1992;215-221.
24. Juven-Gershon T., Oren M. Mdm2: the ups and downs. Mol. Med. 5:1999;71-83.
25. Momand J., et al. MDM2-master regulator of the p53 tumor suppressor protein. Gene. 242:2000;15-29.
26. Kubbutat M.H., et al. Analysis of the degradation function of Mdm2. Cell Growth Differ. 10:1999;87-92.
27. Tao W., Levine A.J. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc. Natl. Acad. Sci. U. S. A. 96:1999;3077-3080.
28. Kamijo T., et al. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. U. S. A. 95:1998;8292-8297.
29. Tao W., Levine A.J. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc. Natl. Acad. Sci. U. S. A. 96:1999;6937-6941.
30. Honda R., et al. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:1997;25-27.
31. Lill N.L., et al. Binding and modulation of p53 by p300/CBP coactivators. Nature. 387:1997;823-827.
32. Grossman S.R., et al. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol. Cell. 2:1998;405-415.
33. Maehama T., et al. PTEN and myotubularin: novel phosphoinositide phosphatases. Annu. Rev. Biochem. 70:2001;247-279.
34. Myers M.P., et al. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc. Natl. Acad. Sci. U. S. A. 95:1998;13513-13518.
35. Stambolic V., et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 95:1998;29-39.
36. Haas-Kogan D., et al. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr. Biol. 8:1998;1195-1198.
37. Gu J., et al. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J. Cell Biol. 146:1999;389-403.
38. Tamura M., et al. PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival pathway. J. Biol. Chem. 274:1999;20693-20703.
39. Mayo L.D., et al. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J. Biol. Chem. 277:2002;5484-5489.
40. Harbour J.W., Dean D.C. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev. 14:2000;2393-2409.
41. Paramio J.M., et al. PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein. Oncogene. 18:1999;7462-7468.
42. Xiao Z.X., et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature. 375:1995;694-698.
43. Hsieh J.K., et al. RB regulates the stability and the apoptotic function of p53 via MDM2. Mol. Cell. 3:1999;181-193.
44. Canman C.E., et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science. 281:1998;1677-1679.
45. Dumaz N., Meek D.W. Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J. 18:1999;7002-7010.
46. Shieh S.Y., et al. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 91:1997;325-334.
47. Maya R., et al. ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev. 15:2001;1067-1077.
48. Shayesteh L., et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. 21:1999;99-102.
49. Philp A.J., et al. The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res. 61:2001;7426-7429.
50. Ruggeri B.A., et al. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol. Carcinog. 21:1998;81-86.
51. Maier D., et al. Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in low-grade and high-grade gliomas. Oncogene. 16:1998;3331-3335.
52. Li J., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 275:1997;1943-1947.
53. Liaw D., et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 16:1997;64-67.
54. Marsh D.J., et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum. Mol. Genet. 7:1998;507-515.
55. Greenblatt M.S., et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:1994;4855-4878.
56. Hollstein M., et al. p53 mutations in human cancers. Science. 253:1991;49-53.
57. Asselin E., et al. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res. 61:2001;1862-1868.
58. Page C., et al. Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res. 20:2000;407-416.
59. Razzini G., et al. Novel functional PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines. FASEB J. 14:2000;1179-1187.
60. Mills G.B., et al. The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin. Oncol. 28:2001;125-141.
61. Ashcroft M., Vousden K.H. Regulation of p53 stability. Oncogene. 18:1999;7637-7643.
62. Wu X., et al. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7:1993;1126-1132.
63. Stambolic V., et al. Regulation of PTEN transcription by p53. Mol. Cell. 8:2001;317-325.